Skip to main content
Transparency data

Science performance report 2025/2026: FSA Business Committee

Published 14 September 2026

Applies to England, Northern Ireland and Wales

1. Summary

1.1 This paper is the first annual Science Performance Report. It provides a summary of metrics associated with the delivery of FSA science, the inputs and outputs and how those outputs are used.

1.2 The Business Committee is asked to:

  • review the progress made
  • comment on the performance metrics provided

2. Introduction

2.1 Science is a critical enabler to the FSA’s work as a regulator, and our scientific advice underpins the decisions and activities that protect public health. As well as generating new research and evidence as outlined in our areas of research interest (ARI), our science includes risk assessments, incident response and the evaluation of new food and feed products.

2.2 This report is designed to provide evidence of the value of FSA’s ongoing investment in science and how it is being delivered and used.

2.3 As the first of its kind, this report replaces the quarterly updates previously presented to the Business Committee. This reflects the reality that many science performance metrics make more sense when viewed on an annual rather than monthly/quarterly basis.

2.4 The report is designed to focus on science delivery measures, science resourcing (inputs) and scientific outputs. It specifically does not cover science impact and the outcomes that results from science delivery. This is presented in the Annual Science Update to the full FSA Board.

2.5 The report is structured as follows:

  • science performance: the inputs and investment made by the FSA, demonstrating how this work is being delivered effectively and efficiently
  • publications and engagement: the outputs of our science and research and how they were used

3. Science performance

3.1 The FSA continues to invest in and deliver a strong science programme, maintaining the capability, infrastructure and evidence base needed to support the work of the FSA, now and into the future. Key metrics for FY25/26 are presented below, with full details presented in the annexes.

3.2 Science budget: the science, evidence and research division (SERD) budget was £20.3M, which constitutes over 13% of FSA spend being dedicated to science (as compared to £20.4M for 24/25). Overall, the budget was delivered within tolerance (end of year out turn within 1% of first half forecast, compared with 2% in FY24/25).

3.3 Science staff: in FY25/26 the SERD headcount was 167 FTE, which represents around 10% of the FSA’s total headcount. This is largely stable compared to the previous financial year. We are also maintaining high levels of engagement within our science team. A key metric from the 2025 Civil Service People Survey showed an engagement index score of 70%, above the Civil Service average (64%).

3.4 Research budget: £4.7M was spent on external research (forecast to increase to £5.2M in FY26/27), focused on our highest-priority scientific challenges (as described in the Annual Science Update).

3.5 Research & evidence project delivery: in year, across our 4 research priorities we initiated 38 external projects. We completed 41 research projects, 30 of which started in that year and 11 that had been started in previous years. We started FY26/27 with 23 projects ongoing that were commissioned in FY25/26 or earlier and have a pipeline of new research we will initiate in year.

We have published our ongoing and planned work to increase the awareness of our portfolio of research and enable better collaboration with partners. We also maintain a pipeline of ideas which we can initiate if additional resources materialise. More detail about the distribution of spend and projects across the 4 priorities is in the annex below.

3.6 Risk assessment: in FY25/26 we completed 15 Risk Assessment Evidence Components via our Risk Analysis Process (compared to 19 in FY24/25). Each component is reviewed by the relevant policy team and scored on completeness (did it contain all of the information required for a decision to be made), timeliness (was it provided within the agreed timelines), quality assurance (was it appropriately quality assured for robustness) and fitness for purpose (how fully the evidence met the needs of the policy customer).

In FY25/26 only timeliness and fitness for purpose did not score 100% across all the risk assessment evidence components. The timeliness score for FY25/26 was 87% and was a result of 2 risk assessments being delivered outside of the originally agreed timelines, but this did not affect their usefulness. The overall fit for purpose score was 97% and was the result of one package only scoring 50% (scoring 1 out of 2), due to data gaps in the evidence base to feed into the risk assessment, rather than the quality of the assessment itself.

3.7 Science Advisory Committees (SACs): we hosted and supported 49 meetings of our SACs. We currently have 112 SAC members, and a recruitment is starting in summer 2026 to recruit 23 members to replace 41 members who will be reaching the end of their final term in 2027 and to fill expertise gaps. In the remainder of FY26/27, we will also complete an internal review of all our SACs to consider the outcomes from UK-EU SPS and help us shape how and what the SACs deliver going forward.

3.8 National infrastructure: the FSA continues to invest in the scientific skills and laboratory capabilities required to sustain UK food regulatory science into the future. This includes:

  • maintaining a network of 8 designated NRLs across 6 institutions, with an annual spend of £1.3M. Designated under 5-year contracts, the performance of the NRLs is monitored through a structured review and reporting system. In addition to annual performance reports, each NRL has quarterly performance meetings with the FSA/FSS to review delivery. They are also audited by UKAS, which fulfils our regulatory requirement to ensure NRLs are compliant with Regulation 2017/625

  • supporting the 5 Public Analyst Official Laboratories in England and Wales with grants and training totalling £0.4M. The number of both laboratories and public analysts has remained stable over recent years (no laboratories have shut since 2019). Whilst there is no room for complacency, the proactive efforts of the FSA have helped to create a more robust system to sustain these important national capabilities

3.9 Supporting two fellowships (foodborne disease and toxicology) and 5 PhD studentships (across different food safety and food system related topics).

  • in 2025, the FSA also supported three summer food-related internships on the University of York’s Generation Research programme, providing placements for students from under-represented groups to deliver policy relevant research while helping develop the next generation of food scientists

3.10 Sampling: FSA funded sampling provides intelligence and evidence to support regulatory decision making, risk assessments and policy development, while continuing to support Local Authorities and Official Laboratories in England and Wales. In doing so, it also helps maintain critical national surveillance infrastructure (noted above). In FY25/26, an extensive sampling programme with a total expenditure of £5.4 million included:

  • delivery of the FSA’s the Retail Surveillance Programme which sampled 845 higher risk products, and, amongst other intelligence, it identified widespread labelling non-compliance in Dubai style chocolate products and goat meat (see Annual Science Update for details)
  • supporting 110 Local Authorities across three nations to undertake sampling (largely for food standards) as part of targeted surveillance and official control activities resulting in 2154 samples being taken with a total expenditure of £0.6M
  • undertaking 8 research surveys to generate data for use in risk assessments and policy decisions, including on commodity specific risks relating to chemical contaminants and antimicrobial resistance. This work represented a total expenditure of £0.9M. Two surveys have been completed and published, while the remaining 6 from FY25/26 are ongoing
  • fulfilling statutory food and feed safety monitoring responsibilities, including regulatory sampling of shellfish and associated waters, radiological monitoring and Trichinella monitoring
  • delivery of coordinated reactive sampling and analysis in response to international food safety incidents, such as the cereulide contamination incident affecting infant formula

4. Scientific outputs and engagement

4.1 We continue to ensure that the results of our science and research are published and made accessible to the wider community, and that their usage is monitored.

4.2 To enable this, significant investment has been made over recent years. This has included the development and implementation of our FSA Research and Evidence publications web platform, the use of DOIs to allow publication tracking and the adoption of Altmetrics, as a tool for monitoring the usage of FSA publications. Combined this allows usage and engagement tracking with high granularity.

4.3 Key metrics for our publications and engagement for FY25/26 are presented below, with full details presented in the annexes.

4.4 Research reports: we published 38 research reports which were viewed over 135,000 times with almost 3,000 copies downloaded. Whilst the number of published reports went down from 54 in FY24/25 the views and downloads of those reports went up by 159% and 131%, respectively.

4.5 Risk assessments: we published 33 regulated products safety assessments and risk analysis reports, compared to 80 in FY24/25. We also published 172 rapid risk assessments linked to incidents, an increase of 25 on the previous year. The impact of this work is covered in the Annual Science Update.

4.6 Media uptake: there were 1448 online mentions of FSA research across news, social media, policy and academic sources demonstrating that people are aware of FSA science. This is a 20% decrease from FY24/25 which is indicative of a system-wide change in online and media referencing activity rather than a decline in engagement with, or relevance of, FSA-funded research specifically.

4.7 Policy usage: there have been a total of 32 citations of FSA-published reports (n=6) or FSA-funded research (n=26) in UK and international policies demonstrating that FSA research continues to inform policy discussions. This is a drop of approximately 50% from FY24/25 which, again, is indicative of a global reduction in referencing, not confined to FSA work.

4.8 International reach: 84% of the policy citations were from international sources demonstrating reach beyond the UK.

4.9 Supporting innovation: 43 patent citations were linked to FSA-funded research demonstrating that our investment is supporting wider research, innovation and development. The areas of these patents include food allergy prevention and treatment, nutritional and metabolic health, rapid diagnostic and genomic technologies, microbiology and antimicrobial resistance, cell and tissue engineering, drug development and delivery systems, and data and sequencing technologies.

4.10 FSA Science Newsletter: we continue to publish a regular FSA Science newsletter as a channel for engaging with the wider scientific and food regulatory community. This now has over 3,500 subscribers (a 75% increase on the year before) and the edition from May 2026 can be found here. To subscribe to this and other FSA newsletters, visit this page.

4.11 Science blogs: we published 23 blogs (a 10% increase from the previous year) to make our science more accessible to the public and point them to the detailed research reports if they wanted to learn more.

5. Summary

5.1 This is the first time an annual science performance report has been presented to the Business Committee. In addition to summarising the range of inputs and investments made by the FSA into science across FY25/26, metrics relating to delivery, it also provides measures relating to our scientific outputs and how those have been used.

5.2 This report specifically does not cover the outcomes and impact delivered by FSA science. That is covered in the Annual Science Update, presented to the Board, which should be considered in tandem with this report.

5.3 In presenting this report, the Business Committee is asked to review the progress made and comment on the metrics provided. Given this is the first iteration of this report, feedback on the approach taken and potential improvements for future are welcomed.

Annex 1: distribution of activity across the research priorities

The distribution of our spend in FY25/25 is shown in Figure 1 and our forecast spend for FY26/27 is shown in Figure 2. We changed the structure of our research programmes in FY26/27 hence a direct comparison across the two years is not possible.

Figure 1: actual external research spend in FY25/26. NB £1.5M of the foodborne disease and antimicrobial resistance spend is on the IID3 project. Note the groupings refer to older groupings of our research priorities

Figure 2: forecast external research spend in FY26/27. NB this refers to the current research priorities

Figure 3 shows how our research portfolio aligns to our published Areas of Research Interest (ARI). Figure 3: distribution of projects across the research priorities

Annex 2: engagement metrics

In FY25/26 we had:

The top viewed published articles were:

The top 10 country of origin of the most viewers in FY25/26:

  • Great Britain (59,154 viewers)
  • United States of America (15,157 viewers)
  • Japan (10,155 viewers)
  • Singapore (8,630 viewers)
  • Hong Kong (7,199 viewers)
  • Mexico (5,728 viewers)
  • China (2,565 viewers)
  • India (1,996 viewers)
  • Denmark (1,693 viewers)
  • Brazil (1,452 viewers)

Our most viewed blogs were:

The most frequently mentioned articles (published by the FSA or made possible as a result of FSA collaboration) in the news:

The most frequently mentioned articles (published by the FSA or made possible as a result of FSA collaboration) in social media:

Some examples of where FSA funded or supported research has been mentioned in policies (beyond the work of the FSA):

FSA research also supported the REF case studies submitted by universities to demonstrate the impact of academic research. These include:

  • the University of Aberdeen submitted the Test-Track-and-Tracing Campylobacter case study, citing the FSA funded IID2 final report. The case study highlights how FSA supported research improved understanding of the sources of Campylobacter infection, informing interventions to reduce foodborne illness and strengthen food safety policy
  • the University of Southampton submitted the case study A systems approach to strengthening food security policy.pdf. The case study highlights how FSA investment in research strengthened the evidence base for food security policy, enabling decision makers to better understand and respond to interconnected food system risks
  • St George’s University London submitted the case study Early introduction of allergenic foods and the prevention of food.pdf. The case study highlights how FSA investment in research informed evidence based guidance on infant feeding practices, contributing to improved approaches to food allergy prevention and better public health outcome

Annex 3: list of publications and views (research projects and risk assessments)

The 38 research projects published in FY25-26 (in order of the most attention they received) were:

Research project Page views
An Assessment of the Risk of Companion Animals Acquiring Salmonella spp., Escherichia Coli, Campylobacter spp. and MRSA From Contaminated Raw Pet Food, and Associated Risks to Pet Owners From the Use of These Products in the Home 565  
Safety Assessment of Calcium Tert-Butylphosphonate Used as an Additive for Use in the Manufacture of Plastic Food Contact Materials and Articles (RP1702) 332  
Safety Assessment on the Safety and Efficacy of an Additive Consisting of 6-Phytase Produced by Trichoderma Reesei (Quantum Blue) as a Feed Additive for Use in Fin Fish (RP1275) 253  
Safety Assessment: Outcome of Assessment on an Application Under the Novel Foods Regulation 2015/2283 as Retained in UK Law for Barley Rice Protein 307  
Safety Assessment on the Safety of Cannabidiol (CBD) Isolate as a Novel Food for Use in a Range of Food Categories Including Food Supplements (RP343) 398  
Safety Assessment on the Safety of Cannabidiol (CBD) Isolate as a Novel Food for Use in a Range of Food Categories Including Food Supplements (RP345) 250  
Safety Assessment on the Safety of Cannabidiol (CBD) Isolate as a Novel Food for Use in a Range of Food Categories Including Food Supplements (RP346) 278  
Assessment of a Modification of Specifications of 2’-Fucosyllactose (2’-FL) Produced by a Genetically Modified Strain of Escherichia Coli BL21 (RP2257) 327  
Rapid Risk Assessment for Glycerol in Slushed Ice Drink Products 1358  
Safety Assessment of Mung Bean Protein as a Novel Food for Use in Food (RP32) 713  
Safety Assessment on the Safety and Efficacy of a Feed Additive Containing Endo-1,4-Beta-Xylanase Produced by Aspergillus Niger CBS 109.713, and Endo-1,4-Beta-Glucanase Produced by Aspergillus Niger DSM 18404 for Its Use in All Pigs (RP1880) 240  
Risk to Consumers From Salmonella in Meat Produced by Small Throughput Poultry Abattoirs That Apply Flexibilities in Sampling 411  
Safety Assessment on the Safety and Efficacy of an Additive Consisting of Bacillus Velezensis ATCC PTA-6737 (PB6) Used as a Feed Additive for Use in Turkeys for Fattening, Turkeys Reared for Breeding and All Growing Poultry (RP1696) 229  
Assessment on the Safety and Efficacy of a Feed Additive Consisting of L-isoleucine Produced by Corynebacterium Glutamicum KCCM 80185 for All Animal Species (CJ Europe GmbH) (RP2212) 234  
Risk to Consumers From the Consumption of Red Meat Produced in Small Throughput Slaughterhouses Due to Process Hygiene Criteria Sampling Exemptions 510  
Assessment on the Safety and Efficacy of a Feed Additive Consisting of a Protease (Subtilisin EC 3.4.21.62) and Bacillus Velezensis NRRL B-50508, B. Velezensis NRRL B-50509 and B. Subtilis NRRL B-50510 (Syncra SWI 201 TPT) for Pigs for Fattening and Other Growing Porcine Species (Danisco (UK) Ltd.) (RP2274) 148  
Safety Assessment on the Safety of Cannabidiol (CBD) Isolate as a Novel Food for Use in a Range of Food Categories Including Food Supplements (RP225) 368  
Assessment of Pea and Rice Protein Fermented by Shiitake (Lentinula Edodes) Mycelia as Novel Food for Use in Food (RP1437) 234  
Safety Assessment of Pea Protein Fermented by Shiitake (Lentinula Edodes) Mushroom Mycelia as a Novel Food (RP1759) 251  
Assessment on the Safety and Efficacy of a Feed Additive Consisting of Saccharomyces Cerevisiae CNCM I-1079 for Dogs and All Other Canidae (Lallemand Animal Nutrition UK Ltd.) (RP2105) 208  
Safety Assessment on the Safety of Cannabidiol (CBD) Isolate as a Novel Food for Use in a Range of Food Categories Including Food Supplements (RP61) 336  
Safety Assessment on the Safety of Cannabidiol (CBD) Isolate as a Novel Food for Use in Food Supplements (RP194) 283  
Safety Assessment on the Change of Specification of the Novel Food Schizochytrium sp. Oil Rich in DHA and EPA (RP2180) 364  
Assessment on Astaxanthin-rich Oleoresin From Haematococcus Pluvialis Algae Used as a Novel Food (RP2213) 757  
Assessment on the Safety and Efficacy of a Feed Additive Consisting of 6-Phytase Produced by Trichoderma Reesei (CBS 126897) (Quantum Blue) for All Avian Species and All Porcine Species (RP2006) 409  
Review: Technical Production Methods of Precision-Fermented Foods Identification and Characterisation of Hazards 380  
Safety Assessment on the Safety and Efficacy of the Authorised Feed Additive Patent Blue V, for Its Use in All Non-Food Producing Animals 161  
Assessment on the Safety and Efficacy of a Feed Additive Consisting of Bacillus Subtilis DSM 32324, Bacillus Subtilis DSM 32325 and Bacillus Amyloliquefaciens DSM 25840 (GalliPro Fit and GalliPro Fit 10) for All Poultry (Chr. Hansen A/S) (RP2245) 125  
Assessment on the Safety and Efficacy of a Feed Additive That Contains Spores of Bacillus Paralicheniformis DSM 33902 and Bacillus Subtilis DSM 33903 (Bovacillus 10 and Bovacillus WS) for Use in Dairy Cows and Other Dairy Ruminants (RP2157) 115  
Safety Assessment on the Safety and Efficacy of Bacillus Licheniformis DSM 28710 (B-Act) as a Feed Additive for Piglets, Pigs for Fattening, Minor Growing Porcine Species and All Reproductive Porcine Species (RP2163) 161  
Assessment on the Feed Additive Consisting of Biotin for All Animal Species for the Modification of Its Authorisation (Adisseo, DSM Nutritional Products Ltd., NHU Europe GmbH) (RP2227) 115  
Updated Rapid Risk Assessment: Risks From Cyanobacterial Toxins in the Edible Flesh of Fish Caught From Lough Neagh 109  
Assessment of Tetrahydrocurcuminoids From Turmeric (Curcuma Longa L.) as a Novel Food for Use in Food Supplements (RP2124)